Trial intelligence / Profile preview

DMXAA plus carboplatin and paclitaxel in advanced NSCLC

2004-004340-42Phase 2Completed

Sponsor
Antisoma
Start
Sep 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, open-label trial of vadimezan in non-small cell lung cancer (NSCLC), sponsored by Antisoma. Started Sep 2005; status: completed.

02

Drugs

vadimezan
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on 2004-004340-42.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-004340-42.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call